\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes FET EIC PilotThe number of proposals that was submitted for this call was 902 of which 58 are eligible for funding, of which two with a Flemish coordinator and eight with a partner:
- Universiteit Antwerpen, coordinator, and IMEC partner in “BAM - Super Bio-Accelerated Mineral weathering: a new climate risk hedging reactor technology”
- IMEC, coordinator “MITICS - Mixed Ionic and electronic Transport In Conjugated polymers for bioelectronicS”
- Universiteit Gent, partner “ChronoPilot - Modulating Human Subjective Time Experience”
- KU Leuven, partner “E-pi - Epistemic AI”
- Rousselot BVBA, partner “ENLIGHT - ENable LIGHT- and synthetic biology-driven volumetric bioprinting of functional human tissues”
- KU Leuven, partner “GAMMA-MRI - gamma-MRI: the future of molecular imaging”
- KU Leuven, partner “HERMES - High Efficiency wiReless CMOS transceiver boosted by artificial intelligencE for 6G bandS and beyond”
- KU Leuven, partner “MIRACLE - Photonic Metaconcrete with Infrared RAdiative Cooling capacity for Large Energy savings”
- KU Leuven, partner “NEWmRNA - Synthetic Biology of mRNA”
An overview of the funded proposals, their consortium partners and allocated budgets
Related article
Number of proposals submitted FETOPEN-01-2018-2019-2020 (RIA) - cut-off: 03/06/2020
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
